• Eiger Announces Positive Meeting with FDA on Progeria Program americanpharmaceuticalreview
    September 05, 2018
    Eiger BioPharmaceuticals has received minutes from a pre-investigational new drug (pre-IND) meeting with the Division of Gastroenterology and Inborn Errors Products of the U.S. Food and Drug Administration (FDA) for lonafarnib in the treatment of Hutchins
PharmaSources Customer Service